BCL2 and melanoma: Optimization of chemoradiotherapy and antisense therapy targeting bcl-2 (Table 1) simplifies the treatment that eliminated metastatic B16 melanoma from the mouse liver, since avoids the need of TNF-α, and IFN-γ administration (and their side effects).